AR081204A1 - Pirrolopirazinas como inhibidores de quinasas - Google Patents
Pirrolopirazinas como inhibidores de quinasasInfo
- Publication number
- AR081204A1 AR081204A1 ARP110101698A ARP110101698A AR081204A1 AR 081204 A1 AR081204 A1 AR 081204A1 AR P110101698 A ARP110101698 A AR P110101698A AR P110101698 A ARP110101698 A AR P110101698A AR 081204 A1 AR081204 A1 AR 081204A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- pyrrolo
- pyrazine
- carboxylic acid
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Estos compuestos inhiben la JAK y la SYK y son útiles para el tratamiento de enfermedades autoinmunes e inflamatorias. Reivindicación 1: Un compuesto de la fórmula (1) en la que R es H, ciano, alquilo inferior, R' o *-(R1a)(R1b)(R1c); R' es cicloalquilo, heterocicloalquilo, heteroarilo o fenilo, cada uno está opcionalmente sustituido por uno o más R"; cada R" es con independencia halógeno, hidroxi, ciano, alquilo inferior, haloalquilo interior, alcoxi inferior, hidroxialquilo inferior, cicloalquilo, C(=O)R"' o S(=O)2R'''; cada R"' es con independencia OH o alquilo inferior; R1a y R1b con independencia entre sí son H, hidroxi, halógeno, alquilo inferior, alquenilo inferior, alquinilo inferior, haloalquilo inferior, alcoxi inferior, haloalcoxi inferior, hidroxialquilo inferior, amino, (alquilo inferior)-amino, di(alquilo inferior)-amino, ciano, C(=O)R''', S(=O)2R''' o CH2S(=O)2R"'; R1c es fenilo, cicloalquilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos por uno o más R1d; cada R1d es con independencia hidroxi, halógeno, alquilo inferior, hidroxialquilo inferior, halógeno-alquilo inferior o alcoxi inferior; R2 es H, hidroxi-alquilo inferior, haloalquilo inferior o alquilo inferior; R3 es H, hidroxi, ciano, ciano-alquilo inferior o R3'; cada R3' es con independencia alquilo inferior, hidroxialquilo inferior, alcoxi inferior, haloalquilo inferior, haloalcoxi inferior, fenil-alquilo inferior, cicloalquilo o cicloalquil-alquilo inferior, cada uno de ellos está opcionalmente sustituido por uno o más R3"; cada R3" es con independencia alquilo inferior, halógeno, hidroxi, alcoxi inferior, haloalquilo inferior, hidroxialquilo inferior, oxo, amino, ciano, ciano-alquilo inferior, S(=O)2R3''', C(=O)R3''', cicloalquilo, heterocicloalquilo, heteroarilo o heterocicloalquenilo; cada R3''' es con independencia H, hidroxi o alquilo inferior; Q es Q2, Q3 o Q4; Q2 es heterocicloalquilo, cicloalquilo, cicloalquenilo, heterocicloalquilo fenilo, heteroarilo, biarilo o heterobiarilo, opcionalmente sustituidos por uno o más Q2a; Q2a es Q2b o Q2c; cada Q2b es con independencia halógeno, oxo, hidroxi, -CN, -SCH3, -S(O)2CH3 o -S(=O)CH3; cada Q2c es con independencia Q2d o Q2e; o dos Q2a juntos forman un sistema de anillo bicíclico, opcionalmente sustituido por uno o más Q2b o Q2c; cada Q2d es con independencia -O(Q2e), -S(=O)2(Q2e), -C(=O)N(Q2e)2, -S(O)2(Q2e), -C(=O)(Q2e), -C(=O)O(Q2e), -N(Q2e)C(=O)(Q2e), -N(Q2e)C(=O)O(Q2e) o -N(Q2e)C(=O)N(Q2e)2; cada Q2e es con independencia H o Q2e'; cada Q2e' es con independencia alquilo inferior, fenilo, bencilo, 5, 6,7,8-tetrahidro-naftaleno, haloalquilo inferior, alcoxi inferior, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquilo espirocíclico o heteroarilo, opcionalmente sustituidos por uno o más Q2f; cada Q2f es con independencia Q2g o Q2h; cada Q2g es con independencia halógeno, hidroxi, ciano, oxo, -S(=O)2(Q2i'), -S(=O)2N(Q2i')2, -C(=O)OH, C(=O)N(Q2i')2 o -C(=O)(Q2i'); cada Q2h es con independencia alquilo inferior, alquenilo inferior, haloalquilo inferior, alcoxi inferior, amino, fenilo, bencilo, cicloalquilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos por uno o más Q2i; y cada Q2i es con independencia halógeno, hidroxi, ciano, alquilo inferior, haloalquilo inferior o alcoxi inferior; cada Q2i' es con independencia H o alquilo inferior; Q3 es -O-Q3a, -S-Q3a, -C(=O)(Q3a), -O(CH2)mC(=O)(Q3a), -S(=O)(Q3a), -S(=O)2(Q3a), -N(Q3a)2, -N(Q3a)S(=O)2(Q3a), -N(Q3a)C(=O)(Q3a), -C(=O)N(Q3a)2, N(Q3a)C(=O)N(Q3a)2 o -N(Q3a)(CH2)mC(=O)N(Q3a)2; cada Q3a es con independencia Q3b o Q3c; cada m es con independencia el número 0, 1 o 2; cada Q3b es con independencia H; cada Q3c es con independencia alquilo inferior, haloalquilo inferior, fenilo, 5, 6,7,8-tetrahidro-naftaleno, naftaleno, 2,2-dimetil-2,3-dihidro-benzofuranilo, indanilo, indenilo, indolilo, cicloalquilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos por uno o más Q3d; y cada Q3d es con independencia Q3e o Q3f; cada Q3e es con independencia halógeno, oxo, ciano, hidroxi, -NHS(=O)2(Q3f), -NHC(=O)(Q3f), NHC(=O)N(Q3f)2 o N(Q3f)2; cada Q3f es con independencia H o Q3f'; cada Q3f' es con independencia alquilo inferior, alcoxi inferior, haloalquilo inferior, fenilo, bencilo, cicloalquilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos por uno o más Q3g; y cada Q3g es con independencia halógeno, hidroxi, alquilo inferior, hidroxialquilo inferior, haloalquilo inferior o alcoxi inferior; Q4 es Q4a o Q4b; Q4a es hidroxi, halógeno o ciano; Q4b es alquilo inferior, alcoxi inferior, alquinilo inferior, alquenilo inferior, hidroxialquilo inferior, amino o haloalquilo inferior, opcionalmente sustituidos por uno o más Q4c; cada Q4c es con independencia Q4d o Q4e; cada Q4d es con independencia halógeno, hidroxi o ciano; cada Q4e es con independencia alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, cicloalquilo, fenilo, heterocicloalquilo o heteroarilo, opcionalmente sustituidos por uno o más Q4f; cada Q4f es con independencia hidroxi, halógeno, alquilo inferior, alquenilo inferior, oxo, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior o amino; con la condición de que el compuesto de la fórmula (1) no sea la isopropilamida del ácido 2-tiofen-2-il-5H-pirrolo[2,3-b]-pirazina-7-carboxílico, (4-hidroxi-3,3-dimetil-butil)-amida del ácido 2-ciclopropil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, 2-[1-(7-isopropilcarbamoil-5H-pirrolo[2,3-b]-pirazin-2-il)-piperidin-3-il]-propionato de tert-butilo, tert-butilamida del ácido 2-ciclopropil-5H-pirrolo[2,3-b]-pirazina-7-carboxílico, isopropilamida del ácido 2-ciclo-hexil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-ciclohex-1-enil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-cloro-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-iso-propil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-isopropenil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-(ciclopentil-metil-amino)-5H-pirrolo[2,3-b]pirazina-7-carboxílico, [1-(7-isopropilcarbamoil-5H-pirrolo[2,3-b]pirazin-2-il)-piperidin-3-il]-metil-carbamato de tert-butilo, isopropilamida del ácido 2-(3-metilamino-piperidin-1-il)-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-(ciclopentil-metil-amino)-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-cloro-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-isopropenil-5H-pirrolo [2,3-b]-pirazina-7-carboxílico, isopropilamida del ácido 2-isopropil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-ciclohex-1-enil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, (3-hidroxi-2,2-dimetil-propil)-amida del ácido 2-ciclopropil-5H-pirrolo[2,3b]pirazina-7-carboxílico, ((S)2-hidroxi-1,2-dimetil-propil)-amida del ácido 2-ciclopropil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, tert-butilamida del ácido 2-ciclopropil-5H-pirrolo[2,3-b]pirazina-7-carboxílico, isopropilamida del ácido 2-ciclohexil-5H-pirrolo[2,3-b]-pirazina-7-carboxílico, (3-hidroxi-2,2dimetil-propil)-amida del ácido 2-tiofen-2-il-5H-pirrolo[2,3-b]pirazina-7-carboxílico, [1-(7-isopropilcarbamoil-5H-pirrolo[2,3-b]-pirazin-2-il)-piperidin-3-il]-metil-carbamato de tert-butilo; isopropilamida del ácido 2-(3-metilamino-piperidin-1-il)-5H-pirrolo[2,3-b]pirazina-7-carboxílico, compuesto con ácido trifluoracético; [1-(7-isopropilcarbamoil-5H-pirrolo [2,3-b]pirazin-2-il)-piperidin-3-il]-metil-carbamato de tert-butilo o isopropilamida del ácido 2-(3-metilamino-piperidin-1-il)-5H-pirrolo[2,3-b]pirazina-7-carboxílico, compuesto con ácido trifluoracético; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34650310P | 2010-05-20 | 2010-05-20 | |
US201161475281P | 2011-04-14 | 2011-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR081204A1 true AR081204A1 (es) | 2012-07-04 |
Family
ID=44147585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110101698A AR081204A1 (es) | 2010-05-20 | 2011-05-18 | Pirrolopirazinas como inhibidores de quinasas |
Country Status (11)
Country | Link |
---|---|
US (2) | US20110288067A1 (es) |
EP (1) | EP2571880A1 (es) |
JP (1) | JP2013529204A (es) |
KR (1) | KR20130083386A (es) |
CN (1) | CN103003281A (es) |
AR (1) | AR081204A1 (es) |
BR (1) | BR112012029437A2 (es) |
CA (1) | CA2799904A1 (es) |
MX (1) | MX2012013378A (es) |
RU (1) | RU2012152352A (es) |
WO (1) | WO2011144585A1 (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3354650T (pt) | 2008-12-19 | 2022-06-20 | Vertex Pharma | Compostos úteis como inibidores da cinase atr |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
US8623869B2 (en) | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2013011450A (es) | 2011-04-05 | 2014-02-03 | Vertex Pharma | Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
CN103502249A (zh) | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2014522818A (ja) * | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
BR112014004569A2 (pt) * | 2011-09-01 | 2017-06-13 | F. Hoffmann-La Roche Ag | composto da fórmula i, métodos para tratar condição inflamatória, artrite reumatoide, asma e distúrbio imune, composição farmacêutica e uso do composto |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
IN2014CN02501A (es) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013064445A1 (en) | 2011-11-01 | 2013-05-10 | F. Hoffmann-La Roche Ag | Imidazopyridazine compounds |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CN104159891B (zh) | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
KR101414006B1 (ko) | 2012-05-16 | 2014-07-02 | 한국화학연구원 | 피라진 접합고리 유도체 및 이를 함유하는 살충제 조성물 |
KR20150043323A (ko) * | 2012-08-21 | 2015-04-22 | 에프. 호프만-라 로슈 아게 | 비장 티로신 키나제 억제제로서 피롤로[2,3-b]피라진 |
PT2892900T (pt) | 2012-09-10 | 2017-11-06 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
US9567339B2 (en) | 2013-06-26 | 2017-02-14 | Abbvie Inc. | Primary carboxamides as BTK inhibitors |
CN105940000B (zh) | 2013-10-21 | 2019-12-24 | 盖诺斯克公司 | 取代的嘧啶化合物及其作为syk抑制剂的用途 |
EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
JP6543252B2 (ja) | 2013-12-06 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体 |
JP6494631B2 (ja) | 2013-12-24 | 2019-04-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コルチスタチン類縁体並びにその合成及び使用 |
EP3107544B1 (en) | 2014-02-21 | 2020-10-07 | Principia Biopharma Inc. | Salts and solid form of a btk inhibitor |
MX2016015874A (es) | 2014-06-05 | 2017-03-27 | Vertex Pharma | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
WO2016000615A1 (en) * | 2014-07-02 | 2016-01-07 | Sunshine Lake Pharma Co., Ltd. | Heteroaryl compounds and pharmaceutical applications thereof |
CA2970723C (en) | 2014-12-18 | 2023-09-05 | Principia Biopharma Inc. | Treatment of pemphigus |
CA2984183C (en) | 2015-05-01 | 2021-11-09 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
EP3294298A4 (en) | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
CN105175273A (zh) * | 2015-08-26 | 2015-12-23 | 吴玲 | 制备s-6-羟基-1-氨基茚满的方法 |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
EP3416970A4 (en) * | 2016-02-19 | 2019-07-24 | President and Fellows of Harvard College | ANALOGUES OF CORTISTATIN |
EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
EP3720441A1 (en) * | 2017-12-04 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Pyrrolo[2,3-b]pyrazine compounds as cccdna inhibitors for the treatment of hepatitis b virus (hbv) infection |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4306172A1 (en) * | 2021-03-09 | 2024-01-17 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Use of tricyclic heteroaryl-containing compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6191306B1 (en) | 1999-08-03 | 2001-02-20 | Eastman Chemical Company | Process for the preparation of cyclopropylglycine |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
BRPI0812014A2 (pt) | 2007-05-25 | 2014-11-18 | Elan Pharm Inc | Pirazolopirrolidinas como inibidores de gama secretase, composição farmacêutica compreendendo as mesmas e uso dos referidos compostos |
BRPI0907928A2 (pt) * | 2008-02-25 | 2015-07-28 | Hoffmann La Roche | Inibidores de pirrolopirazina quinase. |
PT2247592E (pt) * | 2008-02-25 | 2011-11-03 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
WO2009106445A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
ES2372908T3 (es) * | 2008-02-25 | 2012-01-27 | F. Hoffmann-La Roche Ag | Inhibidores de la pirrolopirazina quinasa. |
EP2250172B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
US8518945B2 (en) * | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) * | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
-
2011
- 2011-05-17 KR KR1020127032866A patent/KR20130083386A/ko not_active Application Discontinuation
- 2011-05-17 CN CN2011800350156A patent/CN103003281A/zh active Pending
- 2011-05-17 JP JP2013510592A patent/JP2013529204A/ja active Pending
- 2011-05-17 CA CA2799904A patent/CA2799904A1/en not_active Abandoned
- 2011-05-17 BR BR112012029437A patent/BR112012029437A2/pt not_active IP Right Cessation
- 2011-05-17 MX MX2012013378A patent/MX2012013378A/es unknown
- 2011-05-17 WO PCT/EP2011/057911 patent/WO2011144585A1/en active Application Filing
- 2011-05-17 RU RU2012152352/04A patent/RU2012152352A/ru not_active Application Discontinuation
- 2011-05-17 EP EP11719576A patent/EP2571880A1/en not_active Withdrawn
- 2011-05-18 US US13/110,062 patent/US20110288067A1/en not_active Abandoned
- 2011-05-18 AR ARP110101698A patent/AR081204A1/es unknown
-
2014
- 2014-02-04 US US14/172,144 patent/US20140155376A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20140155376A1 (en) | 2014-06-05 |
EP2571880A1 (en) | 2013-03-27 |
JP2013529204A (ja) | 2013-07-18 |
RU2012152352A (ru) | 2014-06-27 |
CA2799904A1 (en) | 2011-11-24 |
CN103003281A (zh) | 2013-03-27 |
US20110288067A1 (en) | 2011-11-24 |
KR20130083386A (ko) | 2013-07-22 |
WO2011144585A1 (en) | 2011-11-24 |
BR112012029437A2 (pt) | 2017-03-07 |
MX2012013378A (es) | 2013-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR081204A1 (es) | Pirrolopirazinas como inhibidores de quinasas | |
AR081203A1 (es) | Pirrolopirazinas como inhibidores de quinasas | |
PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
UY38296A (es) | Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos | |
CO2019000686A2 (es) | Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo | |
AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
AR110405A1 (es) | Compuestos | |
EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
AR089682A1 (es) | Compuestos de piridazina-amida | |
PE20061164A1 (es) | Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 | |
AR087543A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
PE20141938A1 (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
AR070468A1 (es) | Pirrolopirazinas inhibidores de quinasa | |
AR043434A1 (es) | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
PE20120224A1 (es) | Derivados de 1h-imidazo-[4,5-c]-quinolinona | |
AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
PE20141010A1 (es) | Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
AR105911A1 (es) | Inhibidores de hdac8 bicíclicos fusionados [6,6] | |
AR088246A1 (es) | Derivados de etinilo | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
AR091490A1 (es) | Antagonistas de iap | |
AR109990A1 (es) | Derivados de imidazopirazinonas inhibidores de pde1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |